A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

and anti-VEGF drug Avastin (bevacizumab) already has a breakthrough designation from the FDA as a treatment for first-line HCC treatment. If approved, the Tecentriq/Avastin regimen would be the ...

3-year, 4-year and 5-year OS rate of patients who receive Atezo-Bev treatment, stratified by treatment response. 3 years 35.6 52.2 4 years 30.3 52.2 5 years 30.3 47.7 Responder: patients who achieved ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.